Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | RESORT follow-up: radical metastasectomy plus sorafenib in mRCC

Giuseppe Procopio • 12 Feb 2021
GU Cancers 2021
Genitourinary Cancer Kidney Cancer Sorafenib
RESORT

Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses follow-up results from the randomized Phase II RESORT trial (NCT01444807) investigating the efficacy of radical metastasectomy followed by sorafenib versus observation in patients with metastatic renal cell carcinoma (mRCC). The study analyzed data from 68 patients with mRCC, 32 of whom received sorafenib therapy after radical metastasectomy. Recurrence-free survival (RFS) was the primary endpoint of the trial. The trial found that sorafenib after radical metastasectomy in patients with mRCC did not prolong RFS in comparison to observation. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Dr Giuseppe Procopio, MD, has participated in an advisory role for AstraZeneca, Bayer, Ipsen, Janssen, Merckx, MSD Pharmaceuticals, Novartis, Pfizer and BMS.

More from Giuseppe Procopio

MeetUro 31: radiomics for PFS in metastatic clear cell renal cell carcinoma
1:13
MeetUro 31: radiomics for PFS in metastatic clear cell renal cell carcinoma
Giuseppe Procopio • 25 Oct 2026
Further molecular profiling of patients with CDC and RMC in the REPRINT trial
0:40
Further molecular profiling of patients with CDC and RMC in the REPRINT trial
Giuseppe Procopio • 25 Oct 2026
REPRINT: EV and pembrolizumab in collecting duct and renal medullary carcinoma
2:18
REPRINT: EV and pembrolizumab in collecting duct and renal medullary carcinoma
Giuseppe Procopio • 25 Oct 2026
The emerging role of PARP inhibitors in prostate cancer
4:02
The emerging role of PARP inhibitors in prostate cancer
Giuseppe Procopio • 12 Feb 2021

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals